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Background: There are many similarities with regard to contributing cytokines in patients with psoriasis
and osteoporosis. A theory of probable relationship between these two entities has been proposed but
there is no concordant consensus. The aim of this study was to evaluate bonemineral density (BMD) in pa-
tients with psoriasis.
Method andmaterials: This cross-sectional study of BMDwas conductedwith 64 eligible patientswith psoriasis
who were referred to the dermatology clinic of Razi hospital in Tehran, Iran in between 2011 and 2012.
Results: ThemeanT score of femoral neckwas–1.17 and–0.49 inmen andwomen, respectively,whichwas sta-
tistically signiﬁcant (p= .047). Themean T score of the lumbar spinewas –0.93 and –0.30 inmen andwomen,
respectively, but not statistically signiﬁcant (p = .058). In total except with the exclusion of the study site
(femur or lumbar), men andwomen did not have a statistically signiﬁcant differencewith regard to osteoporo-
sis or osteopenia in BMD (p= .114). The Pearson correlation coefﬁcient demonstrated a moderate inverse re-
lationship between age and T score of the femoral neck and lumbar spine (r= –0.419 and –.406, respectively),
which was statistically signiﬁcant (p= .001). Although there was no statistically signiﬁcant relationship be-
tween the Psoriasis Area and Severity Index (PASI) and T scores of the femoral neck (p = .596), a positive
andweak correlationwas observed between the PASI and T scores for the lumbar spine, whichwas statistically
signiﬁcant (r = 0.269; p=.03).
Conclusion: Patients with psoriasis had decreased bone density, whichwasmore signiﬁcant inmen. Prevalence of
osteoporosis showed no statistically signiﬁcant difference when compared with the healthy population in Iran.
© 2017 Published by Elsevier Inc. on behalf ofWomen's Dermatologic Society. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Psoriasis is a chronic, inﬂammatory disorder of the joints, skin,
and immune system with a prevalence of approximately 2% to 4% in
the general population. Several recent studies have implicated sys-
temic inﬂammatory cytokines with the pathogenesis of psoriasis
and suggested that they are responsible for higher internal involve-
ment such as cardiovascular disease, diabetes, and dyslipidemia.
These studies show that psoriasis is a complex disorder (Langley
et al., 2005; Neimann et al., 2006; Ridker, 2010; Schön and
Henning-Boehricke, 2005).nterest to disclose.
hancellor of Research at the
. Goodarzi).
Women's Dermatologic Society. TAt present, despite screening and prevention programs, osteopo-
rosis remains a hidden problem that is less often detected (Poole and
Compston, 2006). Many cytokines including interferon-gamma,
interleukin-6, and TNF-α have been identiﬁed in the pathogenesis
of osteoporosis and these are the same as those involved in the in-
ﬂammation of psoriasis. Some studies have proposed a hypothesis
of association between these two disorders (De Martinis et al.,
2006; Kastelan et al., 2006).
A review of the literature revealed that there are few studies on
the association between cutaneous psoriasis and osteoporosis and
their results are inconsistent. Most of the existing research only fo-
cused on the impact of psoriatic arthritis on the generalized decrease
in bonemineral mass (Frediani et al., 2001). Interestingly, in contrast
with the usual higher average rates of osteopenia-osteoporosis
among women in the health population, a few studies observed a
prevalence amongmenwith psoriasis (Dreiher et al., 2009; Hofbauer
et al., 2006).his is an open access article under the CC BY-NC-ND license (http://creativecommons.
Table 1
Demographic and laboratory data of patients
Value
Number 64
Sex
Male 34 (53.1%)
Female 30 (46.9%)
Age (years)
Mean±SD 43.9±16.8
Min-Max 13-79
Body mass index (kg/m2)
Mean±SD 27.12±4.93
Min-Max 17-44
Activity 18 (28.1%)
Cigarette smoking 13 (20.3%)
Disease duration (years)
Mean±SD 27.12±4.93
Min-Max 1-40
PASI score
Mean±SD 5.5±4.7
Min-Max 0.4-26
Psoriatic arthritis 2 (3.1%)
Serum total calcium (mg/dl)
Mean±SD 9.9±0.5
Min-Max 7.6-10.9
Serum total phosphorus (mg/dl)
Mean±SD 4.7±0.8
Min-Max 2.7-6.7
Serum parathyroid hormone (ng/dl)
Mean±SD 33.9±16.4
Min-Max 7-84
25 (OH) Vit D3 (ng/dl)
Mean±SD 17.2±11.6
Min-Max 2.4-56
ESR
Mean±SD 15.8±6.2
Min-Max 5-30
CRP
Positive 8 (12.5%)
Negative 56 (87.5%)
25 (OH) Vit D3, 25-hydroxycholecalciferol and vitamin D3; CRP, C-reactive protein;
ESR, erythrocyte sedimentation rate; PASI, Psoriasis Area and Severity Index; SD, stan-
dard deviation.
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bone density in patients with chronic plaque-type psoriasis (with or
without arthritis) and probable gender-related predilection among
a group of Iranian patients whowere referred to a dermatology refer-
ral center at the Razi Hospital in Tehran, Iran.
Methods and materials
This cross-sectional study enrolled 64 patients with psoriasis who
were referred to the Razi Dermatology Center in Tehran, Iran
between 2011 and 2012. The patients did not have a history of
other chronic inﬂammatory disorders, endocrine disorders (thyroid,
parathyroid, and gonadal), chronic kidney disease, or liver disease.
For each patient, a questionnaire on demographic data (age, sex),
daily physical activity (subjective as acceptable or not), smoking,
drug history recorded, and body indices including weight and height
weremeasured. The severity of the skin disease on the basis of Psori-
asis Area and Severity Index (PASI) score and the joint involvement
on the basis of the number of joints were determined and recorded.
Blood samples were tested for C-reactive protein (CRP), erythrocyte
sedimentation rate (ESR), 25-hydroxycholecalciferol (25 [OH]) vita-
min D3 (Vit D3), calcium, phosphorus, and parathyroid hormone
levels at the laboratory center of the Razi hospital.
Bonemineral density (BMD) using the dual-energy X-ray absorp-
tiometry (DEXA) method of the lumbar spine (L1-L4) and femoral
neck was performed at the Sina Hospital that is afﬁliated with the
Tehran University of Medical Sciences and the results were recorded
as T-scores and compared between male and female patients.
According to the World Health Organization’s deﬁnition, T score
values between –1 and –2.5 are considered osteopenia and values
smaller than or equal to –2.5 as osteoporosis. Data were analyzed
using SPSS (IBM, North Castle, NY) Version 18 and for the descriptive
analysis, mean, standard deviation, and frequency were calculated
with the t and analysis of variance (ANOVA) tests to compare differ-
ent variable groups. Pearson’s correlation coefﬁcient or nonparamet-
ric equivalents were used for the quantitative data analysis. All tests
were interpreted with a signiﬁcance level of 5%, and in the case of in-
signiﬁcant results, we reported the power of each test.
The study protocol was approved by the Ethics Committee of the
Tehran University of Medical Sciences and after a complete explana-
tion of the study aims to patients, written informed consent forms
were obtained.
Results
Of the 64 patients enrolled in the study, 34 patients (53.1%) were
male and 30 patients (46.9%) were female with a mean age of
43.9±16.8 years. The mean body mass index (BMI) of patients was
27.12±4.93 kg/m2. Forty patients (62.5%) were overweight (BMI
N25). The demographic and laboratory data of patients are shown
in Table 1.
Twenty-nine patients (45.3%) had femoral neck osteopenia and 6
patients (9.4%) had femoral neck osteoporosis. A BMD study of the
lumbar spine showed that 18 patients (28.1%) had osteopenia and
four patients (6.3%) had osteoporosis (Fig 1). A total of 28 patients
(43.8%) had a decrease of bone mass (osteopenia) in either one of
the two sites (femoral or lumbar), and 8 patients (12.5%) had osteo-
porosis in at least one of the two sites (Fig 2).
The mean T score of femoral neck was –1.17 and –0.49 in men
and women, respectively. The difference was –0.68 (95% conﬁ-
dence interval (CI), –0.01 to –1.36), which was statistically signiﬁ-
cant (p = .047). The mean T score of the lumbar spine was –0.93
and –0.30 in men and women, respectively, and the mean difference
was –0.63 (95 CI, –0.02 to –1.28) but not statistically signiﬁcant (p=
.058).A total of 17 male patients (50%) and 11 female patients (36.7%)
had osteopenia. Six male patients (17.6%) and two female patients
(6.7%) had osteoporosis. In these cases, there was no signiﬁcant dif-
ference between the men and women (p= .114).
The Pearson correlation coefﬁcient demonstrated a moderate in-
verse relationship between age and T score of the femoral neck and
lumbar spine (r = – .419 and –.406, respectively), which was signif-
icant in both cases (p= .001). Table 2 shows the average density of
bone mass in patients by age and sex.
No signiﬁcant correlation was observed between BMI and T score
of the lumbar spine and femoral neck (p= .083 and p= .274, respec-
tively). The mean BMI of patients with osteopenia or osteoporosis
also had no signiﬁcant difference when compared with the BMI of
health subjects (p= .382).
Themean T score of the femoral neck and lumbar spine in patients
who smokewas lower than that of healthy subjects (meandifference,
0.35 and 0.63, respectively) although these differences were not sta-
tistically signiﬁcant (p=.413 and p=.124, respectively). In addition,
no signiﬁcant differences were observed in the prevalence of
smoking among osteoporotic, osteopenic, and normal subjects on
the basis of BMD (p= .572).
Furthermore, no signiﬁcant correlation was observed between
disease duration and T score of the femoral neck and lumbar spine
(p= –.133 and p= .150, respectively) and there was no statistically
signiﬁcant difference between the mean disease duration in patients
with osteoporotic, osteopenic and normal BMD (p= .859).
Fig. 1. Prevalence of osteoporosis and osteopenia in patients’ femoral neck and lumbar spine.
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tween PASI and T scores of the femoral neck (p= .596), a correlation
was observed between PASI and T scores of the lumbar spine, which
was positive and weak but signiﬁcant (r = .269, p=0.03). A signiﬁ-
cant difference was not observed between PASI scores of patients
with osteoporotic, osteopenic, and normal BMD (p= .159).
With regard to inﬂammatorymarkers and cytokines, therewas no
signiﬁcant correlation between ESR and T score of the femoral neck or
lumbar spine (p= .230 and p= .844, respectively) and no signiﬁcant
difference was observed in the ESR of patients with an osteoporotic,
osteopenic, or normal BMD (p= .473).
No signiﬁcant difference was observed about the mean T score of
the femoral neck and lumbar spine in patients with positive or nega-
tive CRP levels (p= .589 and p= .608, respectively). The prevalenceFig. 2. Prevalence of osteoporosis and osof positive CRP levels among patients with osteoporotic, osteopenic,
and normal BMD was not different (p= .520).
During the investigation, no signiﬁcant correlation between
serum total calcium and T score of the femoral neck and lumbar
spine (p= .780 and p= .053, respectively) was found. No difference
in serum calcium levels between patients with osteoporotic,
osteopenic, and normal BMD was observed (p= .537).
Serumphosphorus and bonedensity of the femoral neck and lum-
bar spine were not correlated (p= .965 and p = .785, respectively)
and phosphorus serum levels among patients with osteoporotic,
osteopenic, and normal BMD did not differ (p= .920).
A signiﬁcant relationship between the level of parathyroid
hormone and T score of the lumbar spine or femoral neckwas not ob-
served (p= .816 and p= .785, respectively) and the hormone levelsteopenia in patients with psoriasis.
Table 2
Mean bone mineral density on the basis of age and sex
Age group T score Femur T score Lumbar
Male Patients (n = 34) Female Patients (n = 30) Male Patients (n = 34) Female Patients (n = 30)
b20 years –0.84 (1) –0.10 (2) –0.82 (1) –0.74 (2)
20-29 years –0.16 (3) –0.66 (4) –0.26 (3) 0.13 (4)
30-39 years –0.56 (6) 0.02 (4) 0.06 (6) 0.53 (4)
40-49 years –1.1 (14) 0.74 (13) –0.74 (14) 0.40 (13)
50-59 years –1.64 (7) –1.21 (5) –1.30 (7) –0.93 (5)
60-69 years –2.33 (2) –3.68 (1) –1.16 (2) –0.60 (1)
≥70 years –3.13 (1) –1.55 (1) –1.36 (1) –1.59 (1)
204 V. Lajevardi et al. / International Journal of Women's Dermatology 3 (2017) 201–205between patients with osteoporotic, osteopenic, and normal BMD
showed no signiﬁcant difference (p= .671).
Finally, the levels of 25 (OH) and Vit D3 did not differ statistically
signiﬁcant with regard to T score of the femoral neck or lumbar spine
(p= .953 and p= .172, respectively) and vitamin D levels were not
signiﬁcantly different between patients with osteoporotic,
osteopenic, and normal BMD (p= .636).
Table 3 demonstrates the different variables that affect the corre-
lation coefﬁcient of the femoral neck and lumbar spine’s T score.
Table 4 shows the frequencies of these factors in patients with osteo-
porotic, osteopenic, and normal BMD.
Discussion
After observation of the similarities between cytokines that affect
patients with psoriasis and osteoporosis, the theory of a probable re-
lationship between these two entities has strongly emerged
(Kastelan et al., 2006). The present study evaluated patients with
psoriasis with regard to bone density and showed a decreased
BMD, especially in men, although not statistically signiﬁcant. Unfor-
tunately, due to the lack of a control group, it was not possible to
compare the results with healthy controls. However, when using
the results of a national study on the general population of Iran and
after matching the age and sex categories, we could determine that
the BMDof patientswith psoriasis on the basis of T scores shows a re-
duction. For example, in our study, the mean T scores of the femoral
neck in 10 male patients of age 50 to 59 years old and 7 female pa-
tients of the same age group were –1.64 and –1.2, respectively. In a
national Iranian study by Larijani et al. on osteoporosis in male and
female patients of age 50 to 59 years old, these rates were 0.91 and
0.96, respectively (Bagheri et al., 2011; Larijani et al., 2004, 2005).
These T scores are also available for other sex- and age-matched
groups in Iran in studies on the femoral neck and lumbar spine
(Bagheri et al., 2011; Larijani et al., 2004, 2005). It appears that theTable 3
Pearson’s correlation coefﬁcient of the femoral neck and lumbar spine’s T score and risk fac
Femur
T score
Lumbar
T score
Age BMI Disease
Duration
Femur T score 1
Lumbar T score .665a 1
Age –.419a –.406a 1
BMI .219 .139 .203 1
Disease Duration –.133 .150 –.120 .057 1
PASI .068 .269 –.097 .079 .198
Calcium .040 .273 –.324a –.022 .040
Phosphorus .006 .039 –.200 .069 –.146
Parathyroid Hormone –.033 –.046 .137 –.043 –.021
25(OH) Vit D3 –.008 –.194 .159 .150 –.101
ESR –.171 –.028 .137 –.161 –.049
25 (OH) Vit D3, 25-hydroxycholecalciferol and vitamin D3; BMI, body mass index; ESR, ery
a p value b .05.amount of reduction in the bone density of patients with psoriasis
compared with age- and sex-matched groups in a national study is
not statistically signiﬁcant and not in the range of osteoporosis.
In a large meta-analysis study on 21 related studies that analyzed
9657 cases, the prevalence of femoral neck and lumbar spine osteo-
porosis in Iran was approximately 18% (Bagheri et al., 2011), which
was near the results of our study but not comparable because 12.5%
of our patients had osteoporosis in at least one of these two areas.
Other studies on the association between psoriasis and BMD
showed conﬂicting results. A study by Millard et al. (2001) on the Z
score of patients with chronic plaque-type psoriasis compared with
healthy controls showed no signiﬁcant difference. Also, Balato et al.
(2012) examined the prevalence of osteoporosis among patients
with psoriasis in Italy and did not report a signiﬁcant difference in
BMD with the healthy population of Italy. One study (Keller et al.,
2013) showed that patients with osteoporosis had a higher preva-
lence of psoriasis compared with patients without osteoporosis
(1.5% vs. 0.87%). The prevalence of osteoporosis in Iranian studies
has been reported generally lower than those in European and
American studies (Larijani et al., 2004) but our study demonstrated
a higher prevalence of osteoporosis in patients with psoriasis than
in other studies (e.g., 5% in Balato et al., (2012) and 12.5% in our
study), which shows the importance of demographic and climatic
factors as well as races.
Overall, in most studies, women are at higher risk for osteoporo-
sis, bone density loss, and fracture (Bagheri et al., 2011; Larijani
et al., 2004) but in our study, a BMD reduction in men with psoriasis
was higher than inwomenwith psoriasis with 17.6% ofmen and 6.7%
of women showing osteoporosis. The study by Dreiher et al. (2009)
also showed that the prevalence of osteoporosis in men with psoria-
sis was higher than that inwomen and even after controlling for con-
founding variables, osteoporosis had a higher and stronger
association with the male sex (odds ratio [OR]: 1.35 in men; 0.90 in
women).tors of osteoporosis
PASI Calcium Phosphorus Parathyroid
Hormone
25(OH)
Vit D3
ESR
1
.027 1
–.013 .547a 1
–.056 –.260 –.224 1
–.120 .334a .103 –.284a 1
.191 .004 .007 –.108 –.020 1
throcyte sedimentation rate; PASI, Psoriasis Area and Severity Index.
Table 4
Frequencies of factors that affect the bone density in patients with psoriasis and osteo-
porosis, osteopenia, and normal BMD
Osteoporosis Osteopenia Normal BMD p value
Number (%) 8 (12.5%) 28 (43.8%) 28 (43.8%)
Age 57.2±20.8 47.5±16.1 36.5±12.8 .002
Sex
Male 6 (17.6%) 17 (50%) 11 (32.4%)
.114
Female 2 (6.7%) 11 (36.7%) 17 (56.7%)
BMI 25.1±3.3 26.9±3.6 27.8±6.2 .382
Activity 1 (5.6%) 10 (55.6%) 7 (38.9%) .387
Cigarette smoking 2 (15.4%) 7 (53.8%) 4 (30.8%) .572
Disease duration 8±13.2 7.7±9.1 6.7±4.3 .859
PASI 2.9±2.1 6.5±4.1 5.3±5.5 .159
Calcium 9.6±1.4 9.9±0.4 9.8±0.4 .537
Phosphorus 4.6±1.6 4.5±0.8 4.4±0.8 .920
Parathyroid Hormone 41.0±11.0 33.1±14.1 33.9±19.8 .671
25(OH)Vit D3 19.8±8.1 18.3±13.4 15.4±9.7 .636
ESR 14.7±4.6 16.8±5.4 14.7±7.3 .473
CRP 2 (25%) 3 (37.5%) 3 (37.5%) .520
25(OH)Vit D3, 25-hydroxycholecalciferol and vitamin D3; BMD, bonemineral density;
BMI, body mass index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate;
PASI, Psoriasis Area and Severity Index.
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arthritis showed osteoporosis but this rate among women was only
1.75%. This can be explained perhaps by the fact that osteoporosis
in women is usually due to an estrogen deﬁciency and post-
menopausal women are generally at a higher risk for osteoporosis.
In contrast, osteoporosis in men is usually caused by an underlying
systemic disorder and much more a limitation of physical activities.
In psoriasis, a great amount of inﬂammatory cytokines and immuno-
logical events can be an underlying cause of osteoporosis andwomen
with psoriasis are typically at premenopausal age (Dreiher et al.,
2009).
The ﬁndings by Hofbauer and Dreiher are comparable with those
of our study with regard to different sex predilection of bone density
loss in patients with psoriasis. In this study, none of the underlying
factors (nutritional factors such as intake of calcium, phosphorus
and vitamin D3, personal habits such as daily exercise and smoking)
showed a signiﬁcant difference in the association of psoriasis and os-
teoporosis although themean T score of the femoral neck and lumbar
spine in patients who smoked was lower. In the study by Balato et al.
(2012), patients with psoriasis and osteoporosis or osteopenia also
had no signiﬁcant difference with regard to these risk factors.
Logically, the greater severity of the skin involvement and the lon-
ger exposure to the inﬂammatory cytokines causes the higher degree
of bone loss and higher risk of developing osteoporosis; however, our
study found no association between disease duration and/or PASI
score with the prevalence of osteopenia and osteoporosis in patients
with psoriasis. The reduction of bone density in patients with psoria-
sis is associated with the number of involved joints. ESR and CRP
levels are a sign of underlying inﬂammation but these factors did
not show any increase in patients with psoriasis and osteoporosis
comparable with the results of the Dreiher and Hofbauer studies
(Dreiher et al., 2009; Hofbauer et al., 2006).Limitations and recommendations
The most important limitation of this study was a lack of any age-
and sex-matched healthy controls. We also did not exclude patients
with older ages such as menopausal women, patients with a higher
BMI, or smokers who could be confounders of our study. It is highly
recommended that other, larger, and well-designed controlled stud-
ies are conducted with more focus on probable confounders.Conclusion
In this study, patients with psoriasis had decreased BMD, which
was more signiﬁcant in men even though the prevalence of osteopo-
rosis in patients showed no statistically signiﬁcant difference with
the health population of Iran (Bagheri et al., 2011; p = .114). How-
ever, the design of well-controlled studies that are matched for age,
sex, and race are essential. Screening studies for osteoporosis should
be considered in patients with psoriasis and especially in men with
severe and widespread disease who also have other metabolic
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